Dual protease inhibitor therapy.

Studies are investigating drug interactions in dual protease therapies. Thus far, studies show nelfinavir has a beneficial effect on indinavir while indinavir has a limited effect on nelfinavir. Indinavir/nelfinavir studies are ongoing. Small European clinical trials indicate that while ritonavir (400 mg twice daily) and saquinavir (400 mg twice daily) continue to be the only well-validated combination, nelfinavir (750mg bid) and saquinavir-soft gel capsule (800mg tid) may be an option. European studies also indicate that all dual protease inhibitor combinations, including ritonavir/saquinavir, should be used with at least one nucleoside reverse transcriptase inhibitor.